Medical Condition News

RSS

Change in registry protocols leads to underreporting of myeloid malignancies

Researchers at Moffitt Cancer Center in Tampa, Fla., and colleagues from the UF Shands Cancer Center in Gainesville, Fla., have found that cases of myeloid malignancies are being underreported since a change in registry protocols and laboratory practices starting in 2001.

29 Mar 2012

Biochemists determine atomic structure of new ABC transporter

Proteins belonging to the large and important family of ABC transporters have been associated with metabolic diseases and can cause resistance to antibiotics. Biochemists from the University of Zurich and the NCCR Structural Biology have succeeded in determining the atomic structure of a new ABC transporter. The insights gained could give rise to new therapies to treat multi-resistant bacteria, cystic fibrosis or gout, for instance.

29 Mar 2012

BHECN designs new online training modules to treat mental health issues

It's estimated that more than half of all U.S. mental health care takes place at the primary care level and that percentage jumps considerably in rural areas where there often are no mental health practitioners for hundreds of miles. New online training modules have been designed by the Behavioral Health Education Center of Nebraska (BHECN) to help primary care providers better treat patients with mental health issues.

29 Mar 2012

JDRF, iCo Therapeutics partner for iCo-007 Phase II trial in DME

iCo Therapeutics, a Vancouver-based drug reprofiling company and JDRF, the largest charitable funder of type 1 Diabetes (T1D) research have joined forces to investigate a potential new treatment for one of the most common complications of diabetes, diabetic macular edema.

29 Mar 2012

Ember, Joslin aims to utilize brown fat for treatment of obesity and diabetes

Joslin Diabetes Center and Ember Therapeutics, Inc. today announced an agreement aimed at utilizing "brown fat," a type of fat that helps increase energy expenditure within the body, as a novel technique for managing obesity and diabetes. Joslin's Chief Academic Officer, Dr. Ronald Kahn and other Joslin faculty, Drs. Yu-Hua Tseng and Aaron Cypess, have performed pioneering work in this field over the past several years, and were the first to show that a natural protein called BMP7 can help modulate the levels of brown fat.

29 Mar 2012

Increasing incidences of brain tumours calls for more spend on vital research

With more children and people under the age of 40 dying of a brain tumour than any other cancer in the United Kingdom, a leading researcher at Queen's University Belfast is calling for an increase in spending on vital research.

29 Mar 2012

Broad Institute, Novartis develop cancer cell line encyclopedia

Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1,000 human cancer cell lines used in drug research and development. Results of the collaboration, published in the journal Nature and released in advance online today, may allow scientists around the world to use this information to improve cancer clinical trial design and further cancer research.

29 Mar 2012

Navidea announces data from Lymphoseek Phase 3 study on oral and squamous cell cancers

Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.

29 Mar 2012

Depression more prevalent among stroke and transient ischemic attack survivors

Depression is more prevalent among stroke and transient ischemic attack survivors than in the general population, researchers reported in the American Heart Association's journal Stroke.

29 Mar 2012

New treatment approach halts spread of cancer cells into normal brain tissue

Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.

29 Mar 2012

DaVita thanks nearly 1,500 renal social workers during NASW

DaVita Inc., a leading provider of kidney care services that is committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), today thanks its nearly 1,500 social workers for the value and care they provide to patients and their families.

29 Mar 2012

Providing nutritional information may not be encouraging healthy eating habits

A study by Universit- Laval's Maurice Doyon and French and American researchers shows that U.S. consumers know surprisingly more about the fat content of the foods they buy than their French counterparts. Paradoxically, the obesity rate is nearly three times higher in the United States (35%) than it is in France (12%).

29 Mar 2012

Researchers design new treatment approach for invasive brain tumors

Researchers from Emory and the Georgia Institute of Technology have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models.

29 Mar 2012

Study explores the processing of body pictures in binge eating

An investigation published in the current issue of Psychotherapy and Psychosomatics explores the processing of body pictures in binge eating.

29 Mar 2012

New strategy to ensure that GPs advise heavy drinkers to cut down

The new UK alcohol strategy includes a plan to ensure that General Practitioners (GPs) advise heavy drinkers to cut down.

29 Mar 2012

Regulatory agencies approve plans for e-Therapeutics' ETS2101 phase I trials in cancer

e-Therapeutics plc announces that regulatory agencies in the UK and the US have approved plans for phase I trials of the Company's anti-cancer drug ETS2101 and that enrolment of patients into trials in these two countries will begin shortly.

29 Mar 2012

Bariatric surgery may eliminate need for diabetes medication

Diabetes has become an epidemic in the United States, with the number of cases tripling over the last three decades. Most of those cases are Type 2 diabetes, which is linked to obesity and can lead to serious medical issues that range from heart disease to renal failure, blindness, and more.

29 Mar 2012

Researchers describe unexpected role of p75NTR in type 2 diabetes

Scientists at the Gladstone Institutes have discovered a key protein that regulates insulin resistance-the diminished ability of cells to respond to the action of insulin and which sets the stage for the development of the most common form of diabetes. This breakthrough points to a new way to potentially treat or forestall type 2 diabetes, a rapidly growing global health problem.

29 Mar 2012

EMA grants orphan designations to Ultragenyx UX001, UX003 for treatment of HIBM and MPS 7

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7.

29 Mar 2012

Bristol-Myers Squibb, Meso Scale Discovery collaborate to advance AD research

Bristol-Myers Squibb Company and Meso Scale Discovery today announced they have entered an agreement to develop diagnostic assays that will measure cerebrospinal fluid biomarkers for use in Alzheimer's disease research.

29 Mar 2012